Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries

10+ emerging markets, Japan & ANZ transition in final phase

Biocon Biologics recognized as an Asia IP Elite for 2023

Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list

Cipla to further invest Rs. 42 crore in GoApptiv

Expands patient reach to remotest towns by furthering investment in GoApptiv

Lupin Diagnostics opens new laboratory in Chennai

The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies

Zydus inks licensing agreement with Daewoong Pharmaceutical for leuprolide injectable in the US

The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome

Zydus receives final approval from the USFDA for methylene blue injection

Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product

Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare

The divestment is a part of Fortis' ongoing portfolio rationalization strategy

Mandaviya visits Jan Aushadhi stall at IITF

Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr